Capital Research Global Investors Reduces Stake in iRhythm Technologies

The investment firm sold over 300,000 shares of the medical technology company in the third quarter.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, reduced its position in iRhythm Technologies (NASDAQ:IRTC) by 21.4% during the third quarter of 2026. The firm sold 323,128 shares, leaving it with 1,183,736 shares, or about 3.67% ownership of the company.

Why it matters

iRhythm Technologies is a prominent player in the wearable cardiac monitoring device market, and changes in ownership by large institutional investors can signal shifts in market sentiment and future performance expectations for the company.

The details

According to a 13F filing with the SEC, Capital Research Global Investors sold the shares of iRhythm Technologies, a medical technology company that develops wearable heart rhythm monitoring devices and associated data analytics services. The firm now owns about 3.67% of iRhythm's outstanding shares, down from a previous stake of around 4.67%.

  • The share sale occurred during the third quarter of 2026.

The players

Capital Research Global Investors

A major institutional investment firm that manages over $2 trillion in assets globally.

iRhythm Technologies

A medical technology company that develops wearable cardiac monitoring devices and associated data analytics services.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital Research Global Investors' stake in iRhythm Technologies could signal a shift in market sentiment around the company, though the reasons behind the sale are not entirely clear. Investors will likely watch for any further changes in ownership by large institutional investors as an indicator of the company's future performance.